Scarica l'app Stockscreener
19.79
3.18%
0.61
Dopo l'orario di chiusura:
19.65
-0.14
-0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Enterprise value to EBITDA forward of Sarepta Therapeutics, Inc. – LSE:0L35 - TradingView
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® - Sarepta Therapeutics
Sarepta Refused FDA’s Request to Halt Elevidys Shipments - MSN
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Trading Systems Reacting to (SRPT) Volatility - Stock Traders Daily
SRPTSarepta Therapeutics Inc Volatility & Greeks - Finviz
ETFs Investing in Sarepta Therapeutics, Inc. Stocks - TradingView
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Sarepta Therapeutics Jumps 6.5% Amid Sector-Wide Rally - AlphaStreet
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs - Sahm
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail - BioSpace
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5 - Moomoo
SRPT Stock Quote Price and Forecast - CNN
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
FDA Accepts sNDAs for Sarepta's AMONDYS 45 and VYONDYS 53, Targeting Traditional Approval in Duchenne - BioPharm International
FDA Accepts Sarepta's Applications for Full Approval of Two DMD Treatments - Intellectia AI
SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies - Stocktwits
Mizuho reiterates Sarepta stock rating after FDA filing acceptance By Investing.com - Investing.com Canada
Why is Sarepta Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Sarepta stock jumps as FDA accepts DMD drug applications - Investing.com UK
Sarepta stock jumps as FDA accepts DMD drug applications By Investing.com - Investing.com Nigeria
Sarepta (SRPT) Seeks Traditional Approval for Duchenne Therapies - GuruFocus
FDA accepts Sarepta filings for two Duchenne therapies - Investing.com
FDA accepts Sarepta filings for two Duchenne therapies By Investing.com - Investing.com Canada
FDA to review Sarepta’s Duchenne drugs, with decision due Feb. 28, 2027 - Stock Titan
Sarepta Therapeutics (SRPT) Following FDA Filings And The Case For A Reset Valuation - Sahm
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from Russell 1000 Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Value Benchmark - marketscreener.com
Sarepta Therapeutics (SRPT) Stock Analysis: Unveiling a 30% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from Russell 1000 Dynamic Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Value Benchmark - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutic - The National Law Review
Investors SueWallSt as Sarepta Therapeutics, Inc. Faces Securities Fraud Allegations - The National Law Review
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Did You Lose Money on Sarepta Therapeutics, Inc. (SRPT)? Levi & K - The National Law Review
Class Action Lawsuit Filed: Sarepta Therapeutics, Inc. (SRPT) – Join by August 25, 2025Contact Levi & Korsinsky - The National Law Review
Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025Sarepta Therapeutics, Inc. (SRPT) - The National Law Review
Class Action Lawsuit Filed Against Sarepta Therapeutics, Inc. (SR - The National Law Review
Sarepta Therapeutics Rises As Gene Therapy Outlook Strengthens - StocksToTrade
SRPT Rises As Sarepta Gains Gene Therapy Momentum - timothysykes.com
SRPT Jumps As Sarepta Wins Tailwinds In Gene Therapy - StocksToTrade
Sarepta Therapeutics Stock Firms As Gene Therapy Tailwinds Build - timothysykes.com
Sarepta Therapeutics, Inc. Actuals & Estimates (BMV:SRPT) - TradingView
Sarepta Therapeutics, Inc. Actuals & Estimates (FWB:AB3A) - TradingView
Sarepta Therapeutics, Inc. Actuals & Estimates (BIVA:SRPT) - TradingView
SRPT Forecast — Price Target — Prediction for 2027 - TradingView
Sarepta Therapeutics, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh - TradingView
Sarepta Therapeutics (SRPT) Short Interest & Short Float | Updated Jun 2026 $SRPT - MarketBeat
SRPT or PRTA: Which Is the Better Value Stock Right Now? - Yahoo Finance
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - Stock Traders Daily
Cell and Gene Therapy Market Size Surging at 24.8% CAGR | By Key - openPR.com
Barclays Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20 - Moomoo
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Unlocking a 25.5% Upside in the Biotech Sector - DirectorsTalk Interviews
Sarepta Therapeutics (SRPT) Stock Could Be 19% Undervalued As Elevidys Outlook Steadies - Sahm
Analysts Offer Insights on Healthcare Companies: Owlet (OWLT), Praxis Precision Medicines (PRAX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Is Sarepta (SRPT) Quietly Recasting Its Story Around siRNA as Elevidys Awaits Regulators? - Sahm
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):